Elizabeth Anderson

Morici answered directly, reweighting the split toward gross margin driven by productivity, freight and product mix.

Morici declined to give intra-quarter monthly cadence, citing standing practice.

John said ASPs stable with offsetting factors. Lower-stage NOAA/moderate products come at higher gross margin due to less manufacturing/servicing. Productivity gains from 2025 restructuring continuing. Volume leverage expected to grow through the year.

Joe attributed results to market stability (not improvement) plus Align execution: DSO growth, teen portfolio (IPE attachment rate to First at 40%), and DSP touch-up cases.

John attributed expected Q1 ASP improvement to geographic mix (higher-priced regions growing) and product mix shift toward more comprehensive products, but gave no specific quantification.

Joe emphasized ClinCheck Live Plan as both a productivity tool and case conversion enabler (15-minute chairside plans improve close rates), but did not directly address Q4 market color or quantify gross margin impact.

Joe attributed the miss to June specifically, not a full-quarter trend. Described wires-and-brackets shift among orthos not committed to digital who have sunk cost inventory.

Joe highlighted superior imaging capabilities for lab collaboration but declined to quantify growth expectations, noting stronger competitive positioning than prior scanner generations.

John emphasized global breadth of business and sequential improvement expected from Q1 to Q2, noting guidance based on actual data without claims of significant demand disruption.

Joe described Lumina as exceeding expectations on optics, speed, and form factor. John emphasized the full portfolio spanning from new Lumina to certified pre-owned with multiple financing options.

Fred confirmed the gross-profit savings come from more dynamic pricing and own/corporate-brand mix growth, then flagged specialty and implant growth optimism.

Ron said Q1 specialty results in line with expectations with some customer timing effects, expects improved growth going forward. Fred cited customer feedback confirming HSIC's ecosystem value, employee eagerness for change, and universal supplier desire to grow with HSIC as his biggest encouragements.

Ron confirmed guidance assumes stable share count with buyback impact communicated if material. Private label growing faster than branded merchandise providing margin expansion, with value creation initiatives focused on accelerating private label category growth.

Ron confirmed US dental distribution gross margins stabilized in Q3 at Q2 levels with glove pricing stabilization and return to normal promotional activity. Expects Q4 continuation. Medical margins affected by seasonal flu vaccine mix and strong pharmaceutical growth (both lower-margin).

Stanley described orthodontics as under $100M and immaterial. Traditional products stabilized after generic competition, upgraded product performing well on a reduced cost base. Aligners consolidated to one French factory. Not a big strategic area but turning profitable.

Ron confirmed H2-weighted EPS with Q3 growth and Q4 potentially exceeding Q3, driven by July momentum, equipment backlog recovery, Tapered Pro Conical sequential growth, and value creation projects. Cautioned that remeasurement gains could add lumpiness.

Stanley described IDS as increasingly B2B-focused with customer momentum limited mainly to the DACH region. Key themes were 3D printing and further digitalization, with preparatory pre-show promotions driving German equipment momentum.

Stanley explained specialty products are mostly manufactured locally, corporate brand sourcing diversification has been underway for several years. Some commodity products like gloves have alternatives (Malaysia), but acknowledged a few quarters of potential challenge if China tariffs persist.

Stanley confirmed no tariff bottom-line impact in guidance, citing glove sourcing shift to Malaysia and adequate anesthetic inventory, with only dental anesthetics from Canada as a potential industry-wide risk.

Stanley detailed the orthodontic losses from patent expiry, infrastructure rightsizing underway, aligner consolidation to French factory, and expectation to return to profitability by Q4 2025.

Girshick said bookings mix shifted toward pre-IND work, a positive sign that early-stage funding and demand are strengthening and will feed later-stage work.

Birgit detailed seasonal patterns across DSA (slow Jan-Feb as budgets approved), biologics testing (manufacturing shutdowns at year-end), and microbial solutions (Q4 budget spend). Affirmed cautious optimism on demand with pharma through restructuring and biotech funding improving.

Jim said China RMS continues to perform well with growing unit volume. Flagged China as a potential expansion opportunity beyond RMS. Biologics returned to Q4 growth due to higher European demand after client-specific challenges in 2025.

Foster said clients show minimal NAMs behavior change except in discovery phase; safety assessment remains unchanged pending scientific validation. Knell broke $70M savings into 5 categories: facility consolidation, workforce rightsizing, procurement, global business services model, and internal automation.

Pease confirmed current book-to-bill range of 0.8x-0.93x is sufficient for guidance and not expecting return above 1x; steady improvement over last 18 months supports the outlook.

Foster said pharma is stable and improving with restructuring largely complete. Biotech is a tale of two cities with smaller companies cash constrained while midsized performing better. DSA net book-to-bill has had steady upward trajectory for 18 months.

Pease confirmed no one-timers in Q1 bookings strength; broadly based with strong large pharma gross bookings and declining cancellations across all client segments.

Foster said customers are digesting the announcement but not fundamentally changing safety study methodology; FDA was already waiving longer-term NHP studies for monoclonal antibodies.

Flavia directly addressed the math, confirming gross and net book-to-bill were flat Q3 to Q4. James added Q1 color on seasonal softness and stable demand expectations.

Bob outlined a three-phase MSO value-creation thesis (integration, sharing capabilities like clinical trials, then new services); RCA is well progressed, OneOncology on track but early. Eva confirmed OneOncology remains neutral to adjusted EPS net of financing on a 12-month basis and OI modestly ahead of plan.

Bob highlighted OneOncology and RCA joint teams now sharing best practices in research, clinical trials, back-office services, and physician recruitment. Weather caused temporary volume impact but rebounded. Jim added both MSOs have been significant contributors to specialty growth for years.

Bob outlined short-term MSO synergies: clinical trial capability sharing across retina and oncology, revenue cycle management leverage. Longer-term: new capabilities and services built at scale across both platforms.

Bob highlighted cross-MSO leverage opportunities: clinical trial expertise shared across retina and oncology, back-office activities like revenue cycle management. Jim noted RCA clinical trial financial performance exceeded expectations.

Bob highlighted strong cultural fit with RCA, meaningful progress on integration and growth opportunities. Customer market adapting well to MSO era. On MFN: too early to call, actively engaged in Washington advocating for provider reimbursement protection.

Bob outlined three pillars: positioning in growing specialty pharma, broad provider base across sites of care, and purpose-driven team investing in innovation. Emphasized long-term growth mindset and active customer learning.

Jim noted clinical trial subdued activity; expects improvement later in FY25. Bob reinforced strategic importance of global footprint and value to biopharma customers.

Bob framed MSO strategy as natural extension of decades-long community provider support, drawing parallel to Good Neighbor Pharmacy model.

CEO noted over 25% Specialty growth in FY2026 with M&A carryover tailwinds, and guided to more of the same but at a lower rate in FY2027, plus continued 20%-plus growth in BioPharma Solutions toward the $1 billion by FY2028 target.

CFO provided specific growth figures for all three businesses and highlighted secular trends, ADS integration progress, and Theranostic pipeline growth.

Jason noted ADS performing at or slightly above expectations, still early for full integration synergies. Core organic growth strong across all three Other businesses with double-digit growth irrespective of M&A. Each investing organically in different ways: at-Home in distribution automation, Nuclear in Theranostics capacity, OptiFreight in pharmacy expansion.

Jason noted Rite Aid volume has dispersed, Cardinal picking up a portion having started from 0% share. Not primary growth driver given broad-based strength. On policy, aligned with administration's access/affordability goals, views changes as neutral to positive for utilization.

Aaron confirmed Q4 shortfall items (bad debt, contractual resolutions) were separate from Investor Day investments. Without them, Pharma would have been above midpoint. Jason added strong momentum across all KPIs exiting FY25 drove confidence to raise FY26.

Aaron framed GMPD shortfall as two discrete items ($17M health costs Q1, $15M WaveMark Q2). Core improvement plan on track with sequential profit improvement expected.

Jason highlighted ongoing simplification across enterprise, automation investments in at-Home reaching record metrics. Nuclear reactors expected back in weeks, volumes to recover within fiscal year.

Brian described ongoing investments in capabilities and technology across all segments, captured in the full-year beat and raise, without breaking out specific operational items.

Management confirmed Oak Street on track with disciplined growth, V28 adaptation, and clinical model optimization; weather and flu impacts were in line with expectations, nothing material to call out.

Nelson confirmed Medicaid trends in line with expectations with strong rate advocacy execution. Maintaining cautious outlook in high trend environment.

Newman broke down 100bps: ~50bps from provider liabilities dating to 2018, ~50bps from worsening IFP risk adjustment via Wakely data. Core MBR outperformance driven by individual MA.

Shah outlined CostVantage government transition for 1/1/26 targeting more sustainable model. Joyner added that Caremark is driving parallel transparent pricing models.

Joyner confirmed Wegovy not in guidance. On tariffs: front store primarily U.S.-sourced, pharma supply chain highly variable, Aetna monitoring for 2026 Medicare bids.

Nelson confirmed 4.5% YoY rate increase on first 40% of renewals in January. Cowhey cautioned next ~40% renewing in Q3 may not achieve same level.